Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress

Treated 20th Subject in Phase 2 PROTECT Study of ProTmune Opened Second Site for Enrollment of FATE-NK100 DIMENSION Study Submitted First-of-Kind IND to FDA for Universal Off-the-Shelf NK Cell Product FT500 Licensed Novel CAR Constructs from Memorial Sloan Kettering Cancer Center for Off-the-Shelf CAR T-cell Immunotherapies /EIN News/ — SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the second quarter ended June 30, 2018. “Our submission to the FDA of an IND application for FT500, a universal, off-the-shelf NK cell cancer immunotherapy derived from a master iPSC line, is a significant milestone for the Company and the field of cell therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “We are excited to be working with the FDA to allow the first U.S. clinical investigation of an iPSC-derived cell therapy and usher in a new era enabling the development, manufacture and delivery of off-the-shelf cell products for the treatment of cancer. I am very pleased with our execution over the first six months of 2018 across the business,… Read full this story

• Mearsk group records 26 percent increase in 2018
• Environmental damage caused by the construction and operation of buildings has hit a record high and now accounts for over a THIRD of all CO2 emissions, UN report reveals
• Future Enterprises Q2 results: Reports net loss of Rs 320 crore
• The two pitfalls that led to SpiceJet's financial debacle
• Adelaide Test, Day 2 report: Aussies to ashes, by Ashwin’s turn
• The Hill's Morning Report - Presented by Mastercard - COVID-19 relief, omnibus talks go down to the wire
• Pinkerton: Operation Warp Speed Vaccine Shows America’s ‘Can-Do’ Spirit Is Back
• Workday Named a Leader in Gartner Magic Quadrant for Cloud Financial Planning & Analysis Solutions
• The Hill's Morning Report - Presented by Mastercard - Congress slogs toward COVID-19 relief, omnibus deal
• Morrisons reports slowing sales growth and 'help' for Ocado

Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlights Operational Progress have 324 words, post on world.einnews.com at August 5, 2018. This is cached page on Movie Breaking News. If you want remove this page, please contact us.